Ustekinumab (Stelara) therapy for Crohn's disease
https://libcat.nshealth.ca/en/permalink/chpams35722
Nova Scotia Health Authority. QEII. Gastroenterology.
Halifax, NS:
Nova Scotia Health Authority
, 2017.
- Pamphlet Number
- 1695
- Available Online
- View Pamphlet
Your healthcare provider believes treatment with a medicine called ustekinumab (Stelara®) may help to manage your Crohn’s disease. In this pamphlet you will find basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include: a brief description of the medicine, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing thi…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. QEII. Gastroenterology
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2017
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (9 p.) : digital, PDF file
- Subjects (MeSH)
- Ustekinumab
- Crohn Disease - drug therapy
- Subjects (LCSH)
- Crohn's disease
- Gastrointestinal agents
- Abstract
- Your healthcare provider believes treatment with a medicine called ustekinumab (Stelara®) may help to manage your Crohn’s disease. In this pamphlet you will find basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include: a brief description of the medicine, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing this treatment.
- Responsibility
- Prepared by: Alison Harding BSc, Jennifer Stewart RN, CCRP, Dr. Des Leddin; Gastroenterology
- Pamphlet Number
- 1695
Vedolizumab (Entyvio) therapy
https://libcat.nshealth.ca/en/permalink/chpams35620
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program.
Halifax, NS:
Nova Scotia Health Authority
, 2022.
- Pamphlet Number
- 1623
- Available Online
- View Pamphlet
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when und…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2022
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (11 p.) : digital, PDF file
- Subjects (MeSH)
- Gastrointestinal Agents
- Colitis, Ulcerative - drug therapy
- Crohn Disease - drug therapy
- Subjects (LCSH)
- Gastrointestinal agents
- Ulcerative colitis
- Crohn's disease
- Specialty
- Medications
- Abstract
- Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when undergoing this treatment are provided.
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 1623
5-Aminosalicylate (5-ASA) for inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams35397
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program.
Halifax, NS:
Nova Scotia Health Authority
, 2022.
- Pamphlet Number
- 1483
- Available Online
- View Pamphlet
5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to controll active ulcerative colitis, or Crohn’s colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2022
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (5 p.) : digital, PDF file
- Subjects (MeSH)
- Inflammatory Bowel Diseases - drug therapy
- Crohn Disease - drug therapy
- Colitis - drug therapy
- Subjects (LCSH)
- Inflammatory bowel diseases
- Crohn's disease
- Colitis
- Abstract
- 5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to controll active ulcerative colitis, or Crohn’s colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.
- Notes
- Previous title: 5-Aminosalicylate (5-ASA)
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 1483
